Date: Thursday, September 24, 2020
Time: 9:00 am - 10:00 am USA Central Daylight Time (CDT), 4:00 pm - 5:00 pm Central European Time (CET)
Speakers: Sahil Seth, TRACTION Group, MD Anderson Cancer Center and Paul Diehl, Ph.D., COO, Cellecta
Adaptive drug-resistance mechanisms allow human tumors to evade treatment through selection and expansion of treatment-resistant clones. Studying clonal evolution using lineage tracing, allows high-resolution tracking of tumorigenic clones in vivo and in vitro, and establishing clonal replica tumors (CRTs). We used these systems to study characteristics of chemo-resistance and metastasis in pancreatic and triple-negative breast cancer (TNBC) tumors, respectively. We uncovered a multitude of functionally heterogeneous sub-populations of cells with differential degrees of drug sensitivity.
A brief overview of Cellecta technologies and a live Q&A session followed the presentation.